Introduction
Factor XII (Hageman Factor) is a plasma serine protease known to be involved in triggering the intrinsic cascade pathway blood coagulation [1]. Factor XII deficiency is a rare genetic blood disorder that causes prolonged clotting of blood in vivo without the presence of protracted clinical bleeding or clotting tendencies. It is passed on by autosomal recessive inheritance [2]. It affects only 1 in 1 million individuals. Factor XII levels are lower in patients of Asian descent than in other ethnic groups [3]. Given the rarity of the disease, there has been no documentation on the incidence and prevalence of Factor XII deficiency in Malaysia.

There has been controversy about whether Factor XII deficiency has any significant effects on the course and outcome of pregnancy. Few papers associate the condition with poor pregnancy outcomes, notably recurrent miscarriage, whereas few other articles unable to find any association between Factor XII deficiency and adverse pregnancy outcome.

In this case report, we present a pregnant lady with Factor XII deficiency who had an uncomplicated pregnancy with a good outcome.

Case History
A 34-year-old lady was referred to the antenatal clinic in Serdang for large for gestational age baby. She was in her fourth pregnancy, having had two spontaneous vertex delivery, followed by a miscarriage. Her antenatal history was uneventful. Her glucose tolerance test was normal.

She was diagnosed with Factor XII Deficiency ten months earlier when she presented with a missed miscarriage of triplets. During that admission, her blood investigation showed prolonged activated partial thromboplastin test (APTT). Her thrombophilia profile was reasonable Prothrombin Time, APTT 180, Normal Factor IX and Factor VIII, and 0% Factor XII. Anti Cardiolipin Antibodies and anti-beta 2 glycoprotein 1 IgG was not detectable. Gemeprost was inserted intravaginally, and she had an uncomplicated miscarriage. There was no excessive vaginal bleeding post-miscarriage. However, she defaulted subsequent follow-up.

Her two previous deliveries before the miscarriage were uncomplicated. There was no excessive blood loss or symptoms suggestive of venous thrombosis. She did not require thromboprophylaxis. There was also no known family history of any blood disorders.

Assessment done showed a singleton fetus with estimated fetal weight 3.6 kg via ultrasound scan. The patient was admitted at 39 weeks for delivery. On examination, she was a morbidly obese lady with a body mass index of 42. Other vital signs were within normal limits.

Blood investigation results were normal. Her haemoglobin level = 11.7 gm/dl, platelet count = 240x10/L, liver function test, urea and electrolytes were normal. Her coagulation profile was as shown...
Table 1: Patient’s coagulation profile and full blood picture result.

| Laboratory test | Result | Normal Range | Laboratory test | Result | Normal Range |
|-----------------|--------|--------------|-----------------|--------|--------------|
| PT              | 12.7   | 11.5-16.5    | Factor XII activity | 0%     | 70-145%      |
| INR             | 0.94   | 0.8-1.1      | Factor VIII      | 57.6%  | 50-150%      |
| APTT            | 110    | 26-39        | IX activity      | 112.9% | 50-150%      |
| APTT ratio      | 3.8    | 0.8-1.3      |                 |        |              |

Full blood picture: Normochromic normocytic picture with anisocytosis. No spherocytes, fragmented cells, or an increase in polychromatic cells seen.

Discussion

Factor XII, known as the Hageman factor, circulates in plasma as an inactive zymogen form of a serine protease. It is part of the intrinsic coagulation cascade and activates factor XI and prekallikrein in vitro [4].

Since coagulation factor XII first discovery in 1955, its deficiency is connected with thrombosis instead of bleeding. Some data have shown that Factor XII deficiency has a prothrombotic effect and is associated with recurrent venous thromboembolism and myocardial infarction [5,6]. One proposed explanation is because of impairment of contact activation related fibrinolytic activity in factor XII deficient patients [7].

However, Girolami has challenged this premise, elucidating that in most cases where thrombosis was associated with Factor XII deficiency, other congenital or acquired prothrombotic risk factors are present, for example, pregnancy, postpartum period, surgery and trauma [8]. The fact was supported by a study by Kosler, who established that factor XII is not a determinant in deep vein thrombosis [9]. It has been suggested that factor XII is not necessary for thrombin formation [10].

Lämmle et al. studied 74 subjects aged 8 to 82 years from 14 Swiss families with FXII deficiency. They reported that none of the 18 homozygotes or double heterozygotes for subjects with FXII deficiency and FXII:C of less than 0.01 U/ml had an abnormal bleeding tendency during surgery [11]. This study concurred with findings of Girolami et al., that factor XII deficiency does not only show any bleeding tendency but also can withstand even major surgical procedures without thrombotic complications [12].

An animal study has shown that Factor XII deficiency is a protective factor against pathological fibrin formation involved in thrombosis without interfering with hemostasis. The research further suggests Factor XII inhibition as a safe and selective strategy in the prevention of stroke and thromboembolic disease [13].

The pregnancy outcomes of mothers with factor XII deficiency has been inconsistent. Several studies reported a higher incidence of recurrent pregnancy loss [9,10]. In the research conducted by Gris et al., 9.4% of women with unexplained recurrent primary miscarriages were found out to have isolated Factor XII deficiency [14]. One study also observed that patients with higher levels of Factor XII antibodies, which subsequently decreased the level of Factor XII, is also associated with recurrent pregnancy loss [15]. Ogasawara et al. reported that Factor XII deficiency is a better predictor for subsequent pregnancy loss in women with recurrent miscarriage (but not protein C, protein S, antithrombin III, or Factor XIII) [16].

A few others reported Factor XII has no detrimental effect on pregnancy and that normal gestation and vaginal delivery are possible even in cases with congenital FXII deficiency [11-13].

Factor XII deficiency is not a causative factor for hemorrhagic tendency, with only mild bleeding reported [17,18]. However, a study by Koster et al. have investigated the effect of Factor XII deficiency on premature delivery and found a positive correlation [19].

In our case, the patient had a history of one mid-trimester miscarriage, and the last pregnancy and delivery were uncomplicated with Factor XII activities of 0%. She also underwent a safe cesarean section. However, it is unknown whether her infant has Factor XII deficiency since no investigation was done on her yet.

In conclusion, the case report highlights that Factor XII deficiency is not associated with any adverse effect on the course and outcome of pregnancy.

Acknowledgement

The authors would like to thank the Director General of Health Malaysia for permission to publish this case report.
References
1. Stavrou E, Schmaier AH. Factor XII: What does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis. Thrombosis Research. 2010; 125: 210-215.
2. https://rarediseases.org/rare-diseases/factor-xii-deficiency/
3. https://www.hemophilia.ca/factor-xii-deficiency/
4. Cool DE, MacGillivray RT. Characterization of the human blood coagulation factor XII gene. Introns/exon gene organization and analysis of the 5'-flanking region. J Biol Chem. 1987; 262: 13662-13673.
5. Halbmayer WM, Mannhalter C, Feichtinger C, et al. [Factor XII (Hageman factor) deficiency: a risk factor for development of thromboembolism. Incidence of factor XII deficiency in patients after recurrent venous or arterial thromboembolism and myocardial infarction]. Wien Med Wochenschr. 1993; 143: 43-50.
6. Mannhalter C, Fischer M, Hopmeier P, et al. Factor XII activity and antigen concentrations in patients suffering from recurrent thrombosis. Fibrinolysis. 1987; 1: 259-263.
7. Levi M, Hack CE, Boer JP de, et al. Reduction of contact activation related fibrinolytic activity in factor XII deficient patients. Further evidence for the role of the contact system in fibrinolysis in vivo. J Clin Invest. 1991; 88: 1155-1160.
8. Girolami A, Randi ML, Gavasso S, et al. The occasional venous thromboses seen in patients with severe (homozygous) FXII deficiency are probably due to associated risk factors: a study of prevalence in 21 patients and review of the literature. J Thromb Thrombolysis. 2004; 17: 139-143.
9. Koster T, Rosendaal FR, Briet E, et al. John Hageman’s factor and deep-vein thrombosis: Leiden Thrombophilia Study. British Journal of Haematology. 1994; 87: 422-424.
10. Burman JF, Chung HI, Lincoln JCR, et al. Role of factor XII in thrombin generation and fibrinolysis during cardiopulmonary bypass. The Lancet. 1994; 344: 1192-1193.
11. Lämmle B, Wullem WA, Huber I, et al. Thromboembolism and Bleeding Tendency in Congenital Factor XII Deficiency - A Study on 74 Subjects from 14 Swiss Families. Thromb Haemost. 1991; 66: 117-121.
12. Girolami A, Ruzzon E, Lombardi AM, et al. Thrombosis-free surgical procedures in severe (Homozygote) factor XII deficiency: report of four additional cases and literature review. Clin Appl Thromb Hemost. 2004; 10: 351-355.
13. Kleinschnitz C, Stoll G, Bendszus M, et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. Journal of Experimental Medicine. 2006; 203: 513-518.
14. Gris J, Ripart-Neveu S, Maugard C. Respective evaluation of the prevalence of haemostasis abnormalities in unexplained primary early recurrent miscarriages. The Nimes Obstetricians and Haematologists (NOHA) Study. Thrombosis and Haemostasis. 1997; 77: 1096-1103.
15. Jones DW, Gallimore MJ, Winter M. Recurrent abortion-antibodies to factor XII or a decrease in factor XII levels? Fertility and Sterility. 2001; 76: 1288.
16. Ogawara MS, Aoki K, Katano K, et al. Factor XII but not protein C, protein S, antithrombin III, or factor XIII is a predictor of recurrent miscarriage. Fertility and Sterility. 2001; 75: 916-919.
17. Matsuura T, Kobayashi T, Asahina T, et al. Is factor XII deficiency related to recurrent miscarriage? Semin Thromb Hemost. 2001; 27: 115-120.
18. Girolami A, Zocca N, Girolami B, et al. Pregnancies and oral contraceptive therapy in severe (homozygous) FXII deficiency: a study in 12 patients and review of the literature. J Thromb Thrombolysis. 2004; 18: 209-212.
19. Ebina Y, Ieko M, Naito S, et al. Low levels of plasma protein S, protein C and coagulation factor XII during early pregnancy and adverse pregnancy outcome. Thromb Haemost. 2015; 114: 65-69.